Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.

Szczegóły
Abstrakt

Tytuł:: Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Autorzy:: Phou S; Department of Pathology, University of California San Diego, La Jolla, California, USA.
Costello C; Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, California, USA.
Kopko PM; Department of Pathology, University of California San Diego, La Jolla, California, USA.
Allen ES; Department of Pathology, University of California San Diego, La Jolla, California, USA.
Źródło:: Transfusion [Transfusion] 2021 Jul; Vol. 61 (7), pp. 2054-2063. Date of Electronic Publication: 2021 May 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: Arlington, Va. : American Association Of Blood Banks
MeSH Terms:: Artifacts*
Blood Grouping and Crossmatching*/methods
Blood Transfusion*
Antibodies, Monoclonal/*immunology
Antineoplastic Agents, Immunological/*immunology
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Blood Group Incompatibility/*blood
Erythrocytes/*immunology
Isoantibodies/*blood
Multiple Myeloma/*therapy
Adult ; Aged ; Aged, 80 and over ; Allografts ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/therapeutic use ; Blood Group Antigens/immunology ; Blood Group Incompatibility/diagnosis ; Blood Group Incompatibility/epidemiology ; Combined Modality Therapy ; Dithiothreitol/pharmacology ; Erythrocytes/drug effects ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Incidence ; Isoantibodies/biosynthesis ; Isoantibodies/immunology ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Transplantation, Autologous
References:: Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551-60.
Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207-19.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754-66.
Quach H, Benson S, Haysom H, Wilkes AM, Zacher N, Cole-Sinclair M, et al. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J. 2018;48:210-20.
Chapuy CI, Nicholson RT, Aguad MD, Chapuy B, Laubach JP, Richardson PG, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55:1545-54.
Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. Transfusion. 1999;39:763-71.
Schonewille H, de Vries RR, Brand A. Alloimmune response after additional red blood cell antigen challenge in immunized hematooncology patients. Transfusion. 2009;49:453-7.
Blumberg N, Peck K, Ross K, Avila E. Immune response to chronic red blood cell transfusion. Vox Sang. 1983;44:212-7.
Karafin MS, Westlake M, Hauser RG, Tormey CA, Norris PJ, Roubinian NH, et al. Risk factors for red blood cell alloimmunization in the recipient epidemiology and donor evaluation study (REDS-III) database. Br J Haematol. 2018;181:672-81.
Chapuy CI, Aguad MD, Nicholson RT, AuBuchon JP, Cohn CS, Delaney M, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56:2964-72.
Cushing MM, DeSimone RA, Goel R, Hsu YS, Parra P, Racine-Brzostek SE, et al. The impact of daratumumab on transfusion service costs. Transfusion. 2019;59:1252-8.
Youssef M, Arnesen C, Arledge C, Langley C, Sylvester D, Sikora J, et al. Validation and cost-effectiveness of an in-house dithiothreitol (DTT) treatment protocol for daratumumab patients in a large tertiary care hospital provides gateway for implementation in smaller community hospitals. Transfus Apher Sci. 2019;58:152-5.
de Vooght KMK, Lozano M, Bueno JL, Alarcón A, Romera I, Suzuki K, Zhiburt E, Holbro A, Infanti L, Buser A, Hustinx H, Deneys V, Frélik A, Thiry C, Murphy M, Staves J, Selleng K, Greinacher A, Kutner JM, Bonet Bub C, Castilho L, Kaufman R, Colling ME, Perseghin P, Incontri A, Dassi M, Brilhante D, Macêdo A, Cserti-Gazdewich C, Pendergrast JM, Hawes J, Lundgren MN, Storry JR, Jain A, Marwaha N, Sharma RR. Vox Sanguinis international forum on typing and matching strategies in patients on anti-CD38 monoclonal therapy: summary. Vox Sang 2018;113: 492-8.
Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, et al. Blood transfusion management for patients treated with anti-CD38 monoclonal antibodies. Front Immunol. 2018;9:2616.
Karafin MS, Tan S, Tormey CA, Spencer BR, Hauser RG, Norris PJ, et al. Prevalence and risk factors for RBC alloantibodies in blood donors in the recipient epidemiology and donor evaluation study-III (REDS-III). Transfusion. 2019;59:217-25.
Issitt P, Anstee D. Applied blood group serology. Durham, NC: Montgomery Scientific Publications; 1998.
Evers D, Middelburg RA, de Haas M, Zalpuri S, de Vooght KM, van de Kerkhof D, et al. Red-blood-cell alloimmunisation in relation to antigens' exposure and their immunogenicity: a cohort study. Lancet Haematol. 2016;3:e284-92.
Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18:44-51.
Ye Z, Wolf LA, Mettman D, Plapp FV. Risk of RBC alloimmunization in multiple myeloma patients treated by Daratumumab. Vox Sang. 2020;115(2):207-12.
US Food and Drug Administration FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma [monograph on the internet] US Food and Drug Administration; 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma.
Godara A, Siddiqui NS, Lee LX, Toskic D, Fogaren T, Varga C, et al. Dual monoclonal antibody therapy in patients with systemic AL amyloidosis and cardiac involvement. Clin Lymphoma Myeloma Leuk. 2020;20:184-9.
Chung A, Kaufman GP, Sidana S, Eckhert E, Schrier SL, Lafayette RA, et al. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Adv. 2020;4:458-66.
Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020;67:e28010.
Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379:1846-50.
Denomme GA, Reinders S, Bensing KM, Piefer C, Schanen M, Curnes J, et al. Use of a cloud-based search engine of a centralized donor database to identify historical antigen-negative units in hospital inventories. Transfusion. 2020;60:417-23.
Yazer MH, Anani WQ, Denomme GA, Karafin MS, Sayers M, Shaz BH, et al. Trends in antigen-negative red blood cell distributions by racial or ethnic groups in the United States. Transfusion. 2018;58:145-50.
Trépanier P, Chevrier MC, Constanzo Yanez J, Baillargeon N, St-Pierre C, Perreault J. Adapting to supply-and-demand emerging trends for antigen-negative red blood cell units. Transfusion. 2021. https://doi.org/10.1111/trf.16285 Epub ahead of print.
Yee MEM, Josephson CD, Winkler AM, Webb J, Luban NLC, Leong T, et al. Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia. Transfusion. 2017;57:2738-46.
D'Agostino M, Gazzera G, Cetani G, Bringhen S, Boccadoro M, Gay F. Clinical and pharmacologic features of monoclonal antibodies and checkpoint blockade therapy in multiple myeloma. Curr Med Chem. 2019;26:5968-81.
Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA phase III study design. Future Oncol. 2020;16:4347-58.
Velliquette RW, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff CM. Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion. 2019;59:730-7.
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37:946-53.
Brierley CK, Staves J, Roberts C, Johnson H, Vyas P, Goodnough LT, et al. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. Transfusion. 2019;59:2248-54.
Grant Information:: University of California
Contributed Indexing:: Keywords: immunohematology (RBC serology, blood groups); transfusion practices (Oncology-Hematology); transfusion service operations
Substance Nomenclature:: 0 (Antibodies, Monoclonal)
0 (Antineoplastic Agents, Immunological)
0 (Blood Group Antigens)
0 (Isoantibodies)
4Z63YK6E0E (daratumumab)
T8ID5YZU6Y (Dithiothreitol)
Entry Date(s):: Date Created: 20210507 Date Completed: 20210813 Latest Revision: 20210813
Update Code:: 20240104
DOI:: 10.1111/trf.16425
PMID:: 33960433
: Czasopismo naukowe

Full Text Finder

Background: Daratumumab, a human anti-CD38 monoclonal antibody used to treat multiple myeloma, interferes with pretransfusion testing and can mask alloantibodies. Incidence of alloimmunization in patients on daratumumab has not been well characterized, and optimal transfusion guidelines regarding prophylactic antigen matching, accounting for both patient safety and efficiency, have not been well established for these patients.
Methods: Records of patients who received daratumumab between January 1, 2014 and July 2, 2019 were reviewed. Daratumumab interference with pretransfusion testing was managed by testing with reagent red blood cells (RBCs) treated with 0.2 M dithiothreitol. When daratumumab was present during antibody testing, patients were transfused with RBC units prophylactically matched for D, C, c, E, e, and K antigens per hospital policy.
Results: Out of 90 patients identified, 52 received a total of 638 RBC transfusions (average of 12.3 units per patient, SD 17.2, range 1-105, median 5 among those transfused). Alloantibodies existing before daratumumab initiation were identified in seven patients. No new alloantibodies were detected in any patients after starting daratumumab treatment.
Conclusions: The incidence of alloimmunization in patients receiving daratumumab is low. Whether this is due to the effect of daratumumab, underlying pathophysiology, or other factors, is unknown. Because these patients require a large number of RBC transfusions overall and have little observed alloimmunization, phenotype matching (beyond RhD) may be unnecessary. Since the use of dithiothreitol cannot rule out the presence of anti-K, we recommend transfusion of ABO-compatible units, prophylactically matched for the D and K antigens only.
(© 2021 AABB.)

Informacja